Huperzine A and Cognition in dementia: what the evidence supports
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Compound or practice
Huperzine A
A potent acetylcholinesterase inhibitor with some dementia data — effectively a drug, not a casual nootropic.
Grade C1 graded outcomerevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Outcome map
Cognition in dementia: what the evidence supports
2 graded interventions for cognition in dementia, ranked by strength of evidence.
Grade C2 graded outcomesrevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
No outcome has the same name in both entries. They may still overlap under different wording — read the two lists below.
Graded only in Huperzine A
- Cognition in dementia Small effectEvidence grade C
Graded only in Cognition in dementia: what the evidence supports
- Huperzine A Small effectEvidence grade C
- Sage Small effectEvidence grade C
Conditions
Only in Huperzine A
- Dementia May improveEvidence grade C
Only in Cognition in dementia: what the evidence supports
None.
What each entry says about the other
- Cognition in dementia: what the evidence supports’s entry · Goes with: Grade C
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.